Status:
RECRUITING
Safety and Efficacy of SBRT in the Treatment of Thoracic Malignant Tumors at Different Sites
Lead Sponsor:
Peking University Third Hospital
Conditions:
Radiotherapy
Thoracic Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
SBRT (stereotactic radiotherapy) can provide a higher dose to the target area without increasing the risk of surrounding normal tissue / organ injury in selective cases. At present, SBRT has been wide...
Eligibility Criteria
Inclusion
- Pathological diagnosis was malignant tumor.
- The location of the target lesion belongs to one of five types and the lesion diameter is ≤ 5cm.
- There is no extensive systemic metastasis or although there is metastasis, the metastasis have been controlled by previous treatment.
- KPS\>70, no serious or uncontrolled underlying diseases, such as severe or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, and patients are expected to be tolerated by radiotherapy.
Exclusion
- Poor basic pulmonary function or symptom correlation caused by various reasons, unable to lie flat or cooperate with treatment.
- The general condition is poor, and the expected survival time is less than 3 months.
- Psychiatric patients or poor compliance, unable to cooperate to complete treatment.
- For other reasons, the researcher believes that it is not suitable to participate in this trial.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05349552
Start Date
May 1 2022
End Date
April 30 2027
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191